206 research outputs found
Acoustic wave controlled X-ray diffraction and emission processes in crystals
Possibilities to exert control over electromagnetic processes in a crystal by an acoustic wave are considered. The influence of such a wave on the parametric X-ray radiation and coherent bremsstrahlung from relativistic electrons in a crystal are studied in this paper
Polarization lidars with conical scanning for retrieving the microphysical characteristics of cirrus clouds
The paper presents the first results of observations of cirrus clouds by polarization lidars with conical scanning, which were developed in Hefei (China) and in Tomsk (Russia). The light scattering matrix of ice crystal particles of cirrus clouds has been calculated for the first by the authors within the framework of the physical optics approximations in the case of conical scanning lidar. It is found that in this case the Mueller matrix consists of ten non-zero elements, four of which are small and canβt be applied to interpret the azimuthal distribution of particle orientation. All the diagonal elements have a strong azimuthal dependence. Among the off-diagonal elements only one element M34 carries additional information for interpreting the azimuthal distribution. Β© (2015) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΉ. ΠΡΠΎΠ±Π»Π΅ΠΌΡ ΠΈΡ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ
The paper deals with the problems of optimizing the diagnostic criteria for idiopathic inflammatory myopathies (IIM), a group of heterogeneousΒ rare autoimmune diseases characterized by inflammatory lesion in the skeletal muscles. The representatives of this group are traditionally consideredΒ to be polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis. The authors detail the history of classification criteria forΒ IIM from those proposed by T.A. Medsger et al. (1970) relying on its clinical picture, laboratory data and instrumental findings, as well as theΒ criteria (including the first introduced exclusion ones) elaborated by A. Bohan and J.B. Peter in 1975, which remain fundamental in both clinicalΒ practice and researches. The basis for the clinical and serological criteria proposed by Y. Troyanov et al. (2005) for IIM is the identificationΒ of myositis-overlap syndromes. The classificational (subtype identification) and therapeutic value of the criteria based on clinical and serologicalΒ characteristics was supported by the Hungarian investigators A. Vancsa et al. (2010) who investigated the relationship between the clinicalΒ and therapeutic characteristics of IIM and positivity for myositis-specific and myositis-associated antibodies. The criteria developed byΒ M.C. Dalakas (1991, 2003) are based on the specific immunopathological features of a histological pattern, which allow the differentiation ofΒ DM, PM, and inclusion-body myositis from other myopathic syndromes. The 2004 European Neuromuscular Center (ENMC) criteria first identifyΒ necrotizing autoimmune myopathy and nonspecific myositis as individual subtypes. The serological classification of IIM, which is based onthe assessment of autoantibodies that play an important role in the pathogenesis of the disease, is of indubitable interest.Β There is an obvious need for the correct and timely diagnosis of both IIM as a whole and its subtypes in particular, which is complicated by theheterogeneity of the latter. The proposed approaches to diagnosing and classifying IIM have their advantages and disadvantages so that workΒ in this direction is yet to be under way.Π‘ΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΠΌ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΉ (ΠΠΠ) β Π³ΡΡΠΏΠΏΡ ΡΠ΅Π΄ΠΊΠΈΡ
Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΊΠ΅Π»Π΅ΡΠ½ΠΎΠΉ ΠΌΡΡΠΊΡΠ»Π°ΡΡΡΡ.Β ΠΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»ΡΠΌΠΈ ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎ ΡΡΠΈΡΠ°ΡΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡ (ΠΠ), Π΄Π΅ΡΠΌΠ°ΡΠΎΠΌΠΈΠΎΠ·ΠΈΡ (ΠM) ΠΈ ΠΌΠΈΠΎΠ·ΠΈΡ Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡΠΌΠΈ. ΠΠΎΠ΄ΡΠΎΠ±Π½ΠΎ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Π° ΠΈΡΡΠΎΡΠΈΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΠΠ, Π½Π°ΡΠΈΠ½Π°Ρ Ρ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Π’.Π. Medsger ΠΈ ΡΠΎΠ°Π²Ρ. (1970), ΠΎΠΏΠΈΡΠ°ΡΡΠΈΡ
ΡΡ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΊΠ°ΡΡΠΈΠ½Ρ, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΡ
Π² 1975 Π³.Β Π. Bohan ΠΈ J.B. Peter ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² (Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π²ΠΏΠ΅ΡΠ²ΡΠ΅ Π²Π²Π΅Π΄Π΅Π½Π½ΡΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΡ), ΠΎΡΡΠ°ΡΡΠΈΡ
ΡΡ ΠΎΡΠ½ΠΎΠ²ΠΎΠΏΠΎΠ»Π°Π³Π°ΡΡΠΈΠΌΠΈ ΠΊΠ°ΠΊ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅, ΡΠ°ΠΊ ΠΈ Π² Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
. Π ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΠΠ Y. Troyanov ΠΈ ΡΠΎΠ°Π²Ρ. (2005) Π»Π΅ΠΆΠΈΡ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ΅ΠΊΡΠ΅ΡΡΠ½ΡΡ
overlap-ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠ² ΠΌΠΈΠΎΠ·ΠΈΡΠ°. ΠΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ (Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ±ΡΠΈΠΏΠΎΠ²) ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅Β ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π², ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ΅, ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΎ Π²Π΅Π½Π³Π΅ΡΡΠΊΠΈΠΌΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠΌΠΈ A. VΠ°ncsa ΠΈ ΡΠΎΠ°Π²Ρ.Β (2010), ΠΊΠΎΡΠΎΡΡΠΌΠΈ ΠΈΠ·ΡΡΠ΅Π½Π° ΡΠ²ΡΠ·Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΠΠ Ρ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΏΠΎ ΠΌΠΈΠΎΠ·ΠΈΡ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΌΒ ΠΈ ΠΌΠΈΠΎΠ·ΠΈΡΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌ. ΠΡΠΈΡΠ΅ΡΠΈΠΈ Π.Π‘. Dalakas (1991, 2003) ΠΎΡΠ½ΠΎΠ²ΡΠ²Π°ΡΡΡΡ Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠΌΠΌΡΠ½ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΡ
Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°ΡΡ ΠΠ ΠΈ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΈΠΎΠ·ΠΈΡ Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΎΡ Π΄ΡΡΠ³ΠΈΡ
Β ΠΌΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠ². Π ΠΊΡΠΈΡΠ΅ΡΠΈΡΡ
European Neuromuscular Centre (ENMC) 2004 Π³. Π²ΠΏΠ΅ΡΠ²ΡΠ΅ Π²ΡΠ΄Π΅Π»Π΅Π½Ρ ΠΊΠ°ΠΊ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΠ΅ ΡΡΠ±ΡΠΈΠΏΡ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½Π°Ρ Π½Π΅ΠΊΡΠΎΡΠΈΠ·ΠΈΡΡΡΡΠ°Ρ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΡ ΠΈ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠΈΠΎΠ·ΠΈΡ. ΠΠ΅ΡΠΎΠΌΠ½Π΅Π½Π½ΡΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΠΠ, ΠΊΠΎΡΠΎΡΠ°Ρ Π±Π°Π·ΠΈΡΡΠ΅ΡΡΡ Π½Π° ΠΎΡΠ΅Π½ΠΊΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π», ΠΈΠ³ΡΠ°ΡΡΠΈΡ
Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.Β ΠΡΠ΅Π²ΠΈΠ΄Π½Π° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈ ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΊΠ°ΠΊ ΠΠΠ Π² ΡΠ΅Π»ΠΎΠΌ, ΡΠ°ΠΊ ΠΈ Π΅Π³ΠΎ ΡΡΠ±ΡΠΈΠΏΠΎΠ² Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΊΠΎΡΠΎΡΠ°ΡΒ ΠΎΡΠ»ΠΎΠΆΠ½ΡΠ΅ΡΡΡ Π½Π΅ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π½ΠΎΡΡΡΡ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
. ΠΡΠ΅Π΄Π»Π°Π³Π°Π΅ΠΌΡΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΠΠ ΠΈΠΌΠ΅ΡΡ ΡΠ²ΠΎΠΈ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ, ΡΠ°ΠΊ ΡΡΠΎ ΡΠ°Π±ΠΎΡΠ° Π² ΡΡΠΎΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΈ Π΅ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠΎΠΈΡ
Efficacy and tolerability of abatacept treatment: results of 12 months observation
Objectives: This article reports 1-year clinical outcomes of patients with rheumatoid arthritis (RA) receiving abatacept (ABA) therapy. Materials and methods: Patients (n=91) with high RA activity (DAS28 = 5.1 Β± 1.0) and an inadequate response on synthetic DMARDs (mainly methotrexate, 70.3%) and biologics (mainly TNF-Ξ± inhibitors, 93%) were included in the study. The majority of patients were middle-aged (49 Β± 13.5) womens, RF (72.5%) and ACPA (77%) positive, with moderate functional impairment - HAQ = 1.4 (0.9-2). ABA were administered IV, 10 mg/kg according to the standard scheme. The evaluation of the effectiveness of the therapy was carried out according to the EULAR / ACR 2011 criteria using SDAI, CDAI, HAQ and the intention to treat approach. Results: ABA led to a significant (
- β¦